Related Experiment Videos
A new digoxin immunoassay substantially free of interference by digoxin immunoreactive factor
F Jiang1, T R Wilhite, C H Smith
1Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, MO 63110, USA.
Therapeutic Drug Monitoring
|April 1, 1995
Summary
The new Roche digoxin assay is accurate and precise for pediatric use. It shows minimal interference from digoxin-like immunoreactive factor (DLIF), making it superior for monitoring young patients.
Area of Science:
- Clinical Chemistry
- Pediatric Pharmacology
Background:
- Digoxin monitoring is crucial in pediatric care.
- Digoxin-like immunoreactive factor (DLIF) can interfere with digoxin assays.
- Evaluating new diagnostic methods for accuracy and interference is essential.
Purpose of the Study:
- To evaluate the new Roche digoxin assay for pediatric use.
- To assess the potential for interference by digoxin-like immunoreactive factor (DLIF).
- To compare the Roche method with established digoxin assays.
Main Methods:
- Compared the Roche digoxin assay with Abbott TDx, American Dade Stratus, and COBAS-FARA.
- Assessed DLIF interference using specimens from neonates, pregnant women, and patients with renal/liver failure.
- Evaluated assay precision and specimen type suitability (serum/plasma).
Main Results:
- The Roche method showed good correlation with established digoxin assays.
- All tested methods showed some DLIF interference.
- The Roche method exhibited the lowest overall DLIF interference.
- The Roche method requires a small specimen volume.
Conclusions:
- The Roche digoxin assay is precise and suitable for pediatric use.
- The Roche method demonstrates superior performance due to minimal DLIF interference.
- This assay is advantageous for monitoring digoxin levels in pediatric patients.